*僅供醫(yī)學(xué)專業(yè)人士閱讀參考
*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。
精彩資訊等你來
參考文獻(xiàn)：
[1]. 王峰, 陳冬良, 王梓賢, 等. 不可切除的轉(zhuǎn)移性結(jié)直腸癌患者接受姑息治療的中國現(xiàn)狀調(diào)查. 中華胃腸外科雜志, 2024, 27(7): 718-725.
[2]. Argiles G, Arnold D, Prager G, et al. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open. 2019; 4(2): e000495.
[3]. Lv W, Liu B, Feng T, et al. A multi-cohort study of treatment regimens for metastatic colorectal cancer (mCRC) :Subgroup analysis of sequential therapy between Fruquintinib and Regorafenib.2025AACR CT085
[4]. Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496.
[5]. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
[6]. Lonardi S, Dasari A, Tabernero J, et al. Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. 2025 ASCO GI 171.
審批號(hào)：NP-AYT-25N332-Valid Until-2027-April
本資料由和黃醫(yī)藥提供支持
本資料旨在促進(jìn)醫(yī)藥信息的溝通和交流，而非廣告宣傳。本資料內(nèi)容不能以任何方式取代專業(yè)的醫(yī)療指導(dǎo)，也不應(yīng)被視為診療建議。若您想了解更多有關(guān)疾病知識(shí)的信息，請咨詢醫(yī)療衛(wèi)生專業(yè)人士。
* 此文僅用于向醫(yī)學(xué)人士提供科學(xué)信息，不代表本平臺(tái)觀點(diǎn)
熱門跟貼